Timber Pharmaceuticals Inc. [AMEX: TMBR] loss -2.52% or 0.0 points to close at $0.11 with a heavy trading volume of 2701833 shares. The company report on September 14, 2022 that Timber Pharmaceuticals Receives Positive Opinion on Orphan Designation from European Medicines Agency for TMB-001 for Treatment of Autosomal Recessive Congenital Ichthyosis.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
European Commission expected to issue its decision on orphan designation in approximately 30 days.
It opened the trading session at $0.11, the shares rose to $0.11 and dropped to $0.11, the range by which the price of stock traded the whole day. The daily chart for TMBR points out that the company has recorded -72.06% loss over the past six months. However, it is still -22.22% lower than its most recent low trading price.
If we look at the average trading volume of 13.36M shares, TMBR reached to a volume of 2701833 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Timber Pharmaceuticals Inc. [TMBR]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for TMBR shares is $1.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on TMBR stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
The Average True Range (ATR) for Timber Pharmaceuticals Inc. is set at 0.01, with the Price to Sales ratio for TMBR stock in the period of the last 12 months amounting to 28.21. The Price to Book ratio for the last quarter was 5.41, with the Price to Cash per share for the same quarter was set at 0.06.
Trading performance analysis for TMBR stock
Timber Pharmaceuticals Inc. [TMBR] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.64. With this latest performance, TMBR shares dropped by -11.53% in over the last four-week period, additionally sinking by -72.06% over the last 6 months – not to mention a drop of -87.98% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TMBR stock in for the last two-week period is set at 41.07, with the RSI for the last a single of trading hit 42.29, and the three-weeks RSI is set at 39.28 for Timber Pharmaceuticals Inc. [TMBR]. The present Moving Average for the last 50 days of trading for this stock 0.1369, while it was recorded at 0.1117 for the last single week of trading, and 0.2734 for the last 200 days.
Timber Pharmaceuticals Inc. [TMBR]: A deeper dive into fundamental analysis
Return on Total Capital for TMBR is now -762.38, given the latest momentum, and Return on Invested Capital for the company is -1,126.40. Return on Equity for this stock declined to -2,020.23, with Return on Assets sitting at -334.96. Additionally, TMBR Total Debt to Total Capital is recorded at 127.27, with Total Debt to Total Assets ending up at 74.27.
Reflecting on the efficiency of the workforce at the company, Timber Pharmaceuticals Inc. [TMBR] managed to generate an average of -$3,229,000 per employee.Timber Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.40 and a Current Ratio set at 1.40.
An analysis of insider ownership at Timber Pharmaceuticals Inc. [TMBR]
There are presently around $0 million, or 1.40% of TMBR stock, in the hands of institutional investors. The top three institutional holders of TMBR stocks are: VANGUARD GROUP INC with ownership of 1,172,767, which is approximately 0% of the company’s market cap and around 0.40% of the total institutional ownership; GEODE CAPITAL MANAGEMENT, LLC, holding 239,329 shares of the stock with an approximate value of $26000.0 in TMBR stocks shares; and NORTHERN TRUST CORP, currently with $13000.0 in TMBR stock with ownership of nearly 102.349% of the company’s market capitalization.
Positions in Timber Pharmaceuticals Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 10 institutional holders increased their position in Timber Pharmaceuticals Inc. [AMEX:TMBR] by around 252,978 shares. Additionally, 5 investors decreased positions by around 1,067,446 shares, while 3 investors held positions by with 573,114 shares. The mentioned changes placed institutional holdings at 1,893,538 shares, according to the latest SEC report filing. TMBR stock had 3 new institutional investments in for a total of 10,978 shares, while 3 institutional investors sold positions of 93,128 shares during the same period.